We are live on ! Find out more
ACHL

Achilles Therapeutics
ACHL

Delisted

ACHL was delisted on the 20th of March, 2025.

Back to rankings

30 hedge funds and large institutions have $137M invested in Achilles Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 5

50% more funds holding

Funds holding: 20 → 30 (+10)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more capital invested

Capital invested by funds: $137M → $137M (+$371K)

Holders
30
Holders Change
+10
Holders Change %
+50%
% of All Funds
0.46%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
3
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.03M
2
WP
Woodline Partners
California
+$1.96M
3
BlackRock
BlackRock
New York
+$1.29M
4
Citadel Advisors
Citadel Advisors
Florida
+$342K
5
Renaissance Technologies
Renaissance Technologies
New York
+$155K

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$12M
2
FCM
Farallon Capital Management
California
-$3.51M
3
SFM
Sphera Funds Management
Israel
-$1.89M
4
AAA
Affinity Asset Advisors
New York
-$779K
5
Millennium Management
Millennium Management
New York
-$721K
Name Holding Trade Value Shares
Change 		Change in
Stake
SP
1
Syncona Portfolio
Guernsey
$55.5M +$67.1M +11,086,909 New
RCM
2
RA Capital Management
Massachusetts
$25.1M – – –
BBA
3
Baker Bros. Advisors
New York
$13M – – –
AG
4
Artal Group
Luxembourg
$11.3M – – –
RG
5
Redmile Group
California
$10.5M – – –
O
6
OrbiMed
New York
$7.94M – – –
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$5.01M +$3.03M +500,000 +100%
PA
8
Perceptive Advisors
New York
$3.78M – – –
WP
9
Woodline Partners
California
$1.63M +$1.96M +324,387 New
Axa
10
Axa
France
$1.42M +$20.4K +3,369 +1%
BlackRock
11
BlackRock
New York
$1.06M +$1.29M +212,432 New
Citadel Advisors
12
Citadel Advisors
Florida
$283K +$342K +56,557 New
SCP
13
Sender Company & Partners
New York
$139K +$168K +27,690 New
Millennium Management
14
Millennium Management
New York
$132K -$721K -119,106 -82%
Renaissance Technologies
15
Renaissance Technologies
New York
$128K +$155K +25,533 New
Legal & General Group
16
Legal & General Group
United Kingdom
$124K +$150K +24,755 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$88K – – –
Goldman Sachs
18
Goldman Sachs
New York
$65K +$78.7K +13,000 New
RI
19
RTW Investments
New York
$61K +$74K +12,229 New
JF
20
Jump Financial
Illinois
$55K +$66.6K +11,000 New
Morgan Stanley
21
Morgan Stanley
New York
$32K +$38.4K +6,349 New
UBS Group
22
UBS Group
Switzerland
$26K +$30.4K +5,021 New
Bank of America
23
Bank of America
North Carolina
$23K +$13.1K +2,161 +91%
JP Morgan Chase
24
JP Morgan Chase
New York
$17K +$20.8K +3,437 New
EWM
25
Endurance Wealth Management
Rhode Island
$10K +$12 +2 New
1
2

ACHL Hedge Fund Activity: Q4 2021 in Review

30 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q4 2021, worth a combined $137M — up 0.27% from $137M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ACHL positions and 5 closed out — a net gain of 10 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $3.03M. The largest seller was Boxer Capital, exiting entirely with an estimated $12M sold.

  • 30 institutional investors held Achilles Therapeutics (ACHL) as of Q4 2021, up from 20 in Q3 2021.
  • Funds reported $137M of Achilles Therapeutics stock for Q4 2021, up 0.27% quarter-over-quarter.
  • 15 funds opened new Achilles Therapeutics positions in Q4 2021 and 5 closed out, a net change of +10 holders.
  • The largest Achilles Therapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $3.03M added.
  • The largest Achilles Therapeutics seller in Q4 2021 was Boxer Capital, an estimated $12M sold.

Based on aggregated 13F filings for Q4 2021.